Abstract:Achromobacter xylosoxidans is an aerobic, catalase-positive, non-pigment-forming, Gram-negative, and motile bacterium. It potentially causes a wide range of human infections in cystic fibrosis and non-cystic fibrosis patients. However, developing a safe preventive or therapeutic solution against A. xylosoxidans remains challenging. This study aimed to construct an epitope-based vaccine candidate using immunoinformatic techniques. A. xylosoxidans was isolated from an auto workshop in Lahore, and its identification was confirmed through 16S rRNA amplification and bioinformatic analysis. Two protein targets with GenBank accession numbers AKP90890.1 and AKP90355.1 were selected for the vaccine construct. Both proteins exhibited antigenicity, with scores of 0.757 and 0.580, respectively and the epitopes were selected based on the IC50 value using the ANN 4.0 and NN-align 2.3 epitope prediction method for MHC I and MHC II epitopes respectively and predicted epitopes were analyzed for antigenicity, allergenicity and pathogenicity. The vaccine construct demonstrated structural stability, thermostability, solubility, and hydrophilicity. The vaccine produced 250 B-memory cells per mm3 and approximately 16,000 IgM + IgG counts, indicating an effective immune response against A. xylosoxidans. Moreover, the vaccine candidate interacted stably with toll-like receptor 5, a pattern recognition receptor, with a confidence score of 0.98. These results highlight the potency of the designed vaccine candidate, suggesting its potential to withstand rigorous in vitro and in vivo clinical trials. This epitope-based vaccine could serve as the first preventive immunotherapy against A. xylosoxidans infections, addressing this bacterium's health and financial burdens. The findings demonstrate the value of employing immunoinformatic tools in vaccine development, paving the way for more precise and tailored approaches to combating microbial threats.

Enhanced molecular stability of ApxII antigen during secretion in Corynebacterium glutamicum by rational design

Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.

Cloning, expression and immunogenic characterization of the apxIIA gene of Actinobacillus pleuropneumoniae

A trivalent Apx-fusion protein delivered by E. coli outer membrane vesicles induce protection against Actinobacillus pleuropneumoniae of serotype 1 and 7 challenge in a murine model

Construction and Immunogencity of A Delta Apxic/Delta Apxiic Double Mutant of Actinobacillus Pleuropneumoniae Serovar 1

Construction and Immunogenicity of a ∆apxic/ompp2 Mutant of Actinobacillus Pleuropneumoniae and Haemophilus Parasuis.

Potential Use an Actinobacillus Pleuropneumoniae Double Mutant Strain ΔapxIICΔapxIVA As Live Vaccine That Allows Serological Differentiation Between Vaccinated and Infected Animals

Renaturation and Purification of ApxII Toxin of Actinobacillus Pleuropneumoniae

[Cloning and Expression of Hemolytic-Toxin from Actinobacillus Pleuropneumoniae and the Immunoprotection in Mice].

Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

[Construction and Characterization of Actinobacillus Pleuropneumoniae Serovar 7 Live Attenuated Vaccine Strain Co-Expressing ApxIA].

Enhancement of heterologous protein production in Corynebacterium glutamicum via atmospheric and room temperature plasma mutagenesis and high-throughput screening

Genetic and antigenic characteristics of ApxIIA and ApxIIIA from Actinobacillus pleuropneumoniae serovars 2, 3, 4, 6, 8 and 15

Preparation of polyclonal antibodies against chemically synthesized ApxIA and ApxIVA toxins and their diagnostic efficacy in the experimentally injected mice

Construction and Characterization of a Live, Attenuated Apxiica Inactivation Mutant of Actinobacillus Pleuropneumoniae Lacking a Drug Resistance Marker.

Construction and Characterization of an Attenuate Strain Apxic-/P36+ of Actinobacillus Pleuropneumoniae Serovar 10

Identification of proteins of Propionibacterium acnes for use as vaccine candidates to prevent infection by the pig pathogen Actinobacillus pleuropneumoniae

Positive Role for Rapxivn in the Immune Protection of Pigs Against Infection by Actinobacillus Pleuropneumoniae

Identification of Proteins of Pro Pionibacterium Acnes for Use As Vaccine Candidates to Prevent Infection by the Pig Pathogen Actinobacillus Pleuropneumoniae

Identification of Conserved Surface Proteins As Novel Antigenic Vaccine Candidates of Actinobacillus Pleuropneumoniae

Integrating 16S rRNA profiling and in-silico analysis for an epitope-based vaccine strategy against Achromobacter xylosoxidans infection